<DOC>
	<DOCNO>NCT00797966</DOCNO>
	<brief_summary>Primary : To compare efficacy OPC-34712 placebo adjunctive treatment assign open-label market antidepressant treatment ( ADT ) patient demonstrate incomplete response prospective eight week trial assign open-label market ADT .</brief_summary>
	<brief_title>Study Safety Efficacy OPC-34712 Adjunctive Therapy Treatment Patients With Major Depressive Disorder</brief_title>
	<detailed_description>A comparison Fixed dose arm ( OPC-31712 , 0.15 mg ) verse placebo include general secondary efficacy variable result dose group comparison include Outcome Measures .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Male female subject 18 65 year age , diagnosis major depressive disorder , define DSMIVTR criteria The current depressive episode must equal great 8 week duration Subjects must report history current depressive episode inadequate response least one three adequate antidepressant treatment . Females breastfeed and/or positive pregnancy test result prior receive study drug . Subjects report inadequate response three adequate trial antidepressant treatment current depressive episode therapeutic dose adequate duration . Subjects current Axis I ( DSMIVTR ) diagnosis : Delirium , dementia , amnestic cognitive disorder Schizophrenia , schizoaffective disorder , psychotic disorder Bipolar I II disorder Subjects clinically significant current Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>OPC-34712 , Major Depressive Disorder , Adjunctive Treatment</keyword>
</DOC>